0.38
-0.0139(-3.53%)
Currency In USD
| Previous Close | 0.39 |
| Open | 0.39 |
| Day High | 0.39 |
| Day Low | 0.36 |
| 52-Week High | 1.3 |
| 52-Week Low | 0.22 |
| Volume | 1.3M |
| Average Volume | 9.15M |
| Market Cap | 8.22M |
| PE | -0.44 |
| EPS | -0.87 |
| Moving Average 50 Days | 0.41 |
| Moving Average 200 Days | 0.74 |
| Change | -0.01 |
If you invested $1000 in Adial Pharmaceuticals, Inc. (ADIL) since IPO date, it would be worth $3.75 as of August 18, 2025 at a share price of $0.38. Whereas If you bought $1000 worth of Adial Pharmaceuticals, Inc. (ADIL) shares 5 years ago, it would be worth $10.07 as of August 18, 2025 at a share price of $0.38.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire Inc.
Aug 14, 2025 12:30 PM GMT
GLEN ALLEN, Va., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and r
Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting
GlobeNewswire Inc.
Aug 06, 2025 12:00 PM GMT
Meeting Completion Marks Major Step Toward Phase 3 AD04 Trial Launch Strategic Partnership Discussions Expected Following the Positive FDA Meeting GLEN ALLEN, Va., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial
Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders’ Equity Listing Requirement
GlobeNewswire Inc.
Jul 16, 2025 12:30 PM GMT
GLEN ALLEN, Va., July 16, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and r